Highly awaited Alzheimer’s drug hit by delays
Washington (AFP) - Eli Lilly's highly anticipated Alzheimer's drug has been held back for further review by regulators, the US ...
From MagnifyPost
Stories worth a closer look.
Discover fresh perspectives and remarkable reads.
